New Happenings, developments and much more.
Check back regularly or send us a message to update you on new posts.
The NHP activity report for 2023/2024 (published 21 November 2024) gives an overview of its core and partner-related activities.
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
On 25th September 2024, Pfizer announced its voluntarily withdrawing of all lots of OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD).
On 08.08.2024 the National Institute for Health and Care Excellence (NICE) approves NHS use of Casgevy ™ [Exagamglogene Autotemcel (‘Exa-Cel’)] for treatment of Transfusion-dependent beta Thalassaemia
The Founding Chair of the NHP, Professor Baba Inusa, announces his departure from the NHS and his NHP Role in March 2024.
The National Haemoglobinopathy Panel
Women's and Children's Academic Health - Kings College London
Becket House
1 Lambeth Palace Rd
London, SE1 7EU
